Cbay stock forecast.

CBAY stock showed promising performance on November 8, 2023, according to data from CNN Money. The 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc had a median target of 22.50, with a high estimate of 33.00 and a low estimate of 19.00.At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Cymabay Therapeutics (CBAY) Company Description. CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral ...CBAY Stock Shows Promising Performance: Analysts Predict 38.63% Increase CBAY stock had a promising performance on November 6, 2023, based on the information provided by CNN Money. The 12 analysts offering 12-month price forecasts for CymaBay Therapeutics Inc have a median target of 22.50, with a high estimate of 33.00 and a low estimate of 19.00.

The stock is selling for $9.87 and its $13.89 average price target suggests a 12-month upside potential of ~41%. (See CBAY stock forecast ) Cerevel Therapeutics ( CERE )16 brokerages have issued 1-year price targets for Exelixis' stock. Their EXEL share price targets range from $18.00 to $32.00. On average, they expect the company's stock price to reach $25.44 in the next twelve months. This suggests a possible upside of 19.6% from the stock's current price. View analysts price targets for EXEL or view top ...CBAY Earnings Date and Information. CymaBay Therapeutics last posted its earnings results on November 7th, 2023. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.02.

Find the latest Absci Corporation (ABSI) stock quote, history, news and other vital information to help you with your stock trading and investing.Ra Medical Systems, Inc (NYSE:RMED) released its quarterly earnings results on Monday, November, 15th. The company reported ($57.50) earnings per share for the quarter, missing the consensus estimate of ($39.50) by $18.00. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.70 million.

Nov 6, 2023 · Over the past 3 months, 14 analysts have published their opinion on CymaBay Therapeutics (NASDAQ:CBAY) stock. These analysts are typically employed by large Wall Street banks and tasked with ... We’ve all flipped between different weather apps, wondering why each is giving a slightly different report. Before we look at AccuWeather, it’s important to understand the basics of weather forecasting. In the past, weather predictions were...CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline ...According to analyst projections, CBAY’s forecast low is $20.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -82.21% plunge from its current level, while the stock would need to soar -7.18% for it to hit the projected low. Cymabay Therapeutics Inc (CBAY) estimates and forecastsSee the latest CymaBay Therapeutics Inc stock price (CBAY:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Shares of CymaBay Therapeutics ( CBAY -1.16%) were jumping 14.2% higher as of 10:54 a.m. ET on Friday. This move came on the heels of an 8.5% gain on Thursday. The continued momentum is a result ...

Apr 26, 2023 · The stock is selling for $9.87 and its $13.89 average price target suggests a 12-month upside potential of ~41%. (See CBAY stock forecast ) Cerevel Therapeutics ( CERE )

Forecast . Price target. 24.08 0.00 0.00%. The 12 analysts offering 1 year price forecasts for CBAY have a max estimate of — and a min estimate of —. Analyst rating. Based on 13 analysts giving stock ratings to CBAY in the past 3 months. EPS. Annual Annual Quarterly Quarterly More MoreNov 3, 2023 · Cymabay Therapeutics Inc (NASDAQ:CBAY) trade information. Cymabay Therapeutics Inc (CBAY) has traded red over the past five days. The stock hit a weekly high of 16.87 this Thursday, 11/02/23. The 5-day price performance for the stock is 8.04%, and 17.06% over 30 days. With these gigs, the year-to-date price performance is 161.56%. The CymaBay Therapeutics stock forecast for tomorrow is $ 19.01, which would represent a -0.48% loss compared to the current price. In the next week, the price of CBAY is expected to decrease by -5.95% and hit $ 17.96. As far as the long-term CymaBay Therapeutics stock forecast is concerned ... 1,785.90 +6.50(+0.37%) Crude Oil (+0.21%) Advertisement CymaBay Therapeutics, Inc. (CBAY) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M …Nov 24, 2023 · A high-level overview of CymaBay Therapeutics, Inc. (CBAY) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.com

Check out our CBAY stock analysis, current CBAY quote, charts, and historical prices for Cymabay Therapeutics stock ... CBAY Stock Predictions, Articles, and Cymabay Therapeutics News From ...The consensus price target of analysts on Wall Street is $24.42, which implies an increase of 21.66% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20.00 and $34.00 respectively. As a result, CBAY is trading at a discount of -77.73% off the target high and -4.55% off the low.You Should Look At The Stock Forecast For Cymabay Therapeutics Inc (NASDAQ: CBAY). Carlyle Group Inc (NASDAQ: CG): One Stock To Trade As Economic Progress Advances Why Invesco Ltd (NYSE: IVZ) Is A Stock Not To Be Discarded In 2023 Astrazeneca plc ADR (NASDAQ: AZN): A Stock Worth Thinking About Today Procter & …Track Cymabay Therapeutics Inc (CBAY) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsGet the latest CymaBay Therapeutics Inc (CBAY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Their PTGX share price targets range from $32.00 to $38.00. On average, they expect the company's share price to reach $35.25 in the next twelve months. This suggests a possible upside of 109.4% from the stock's current price. View analysts price targets for PTGX or view top-rated stocks among Wall Street analysts.

Xenon Pharmaceuticals Inc. 28.97. +0.24. +0.84%. Get CymaBay Therapeutics Inc (CBAY:NASDAQ) real-time stock quotes, news, price and financial information from …

Crescent Point Energy Corp. (TSE:CPG) issued its quarterly earnings results on Thursday, November, 2nd. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by $0.09. The business earned $1.25 billion during the quarter, compared to analyst estimates of $1.20 billion.At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Dec 1, 2023 · The consensus price target of analysts on Wall Street is $24.42, which implies an increase of 21.66% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20.00 and $34.00 respectively. As a result, CBAY is trading at a discount of -77.73% off the target high and -4.55% off the low. Cymabay Therapeutics (CBAY) Company Description. CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral ...CymaBay Therapeutics (CBAY) Stock Forecast & Price Target $17.90 -0.21 (-1.16%) (As of 11/22/2023 ET) Compare Share Today's Range $17.82 $18.45 50-Day …Nov 29, 2023 · Predictions of CBAY stock price for tomorrow. 14-day Premium Trial Subscription Try For Free Get Free The current CymaBay Therapeutics [ CBAY] share price is $17.90. The Score for CBAY is 74, which is 48% above its historic median score of 50, and infers lower risk than normal. CBAY is currently trading in the 70-80% percentile range relative to its …7 brokers have issued 12-month price targets for Verastem's stock. Their VSTM share price targets range from $21.00 to $36.00. On average, they anticipate the company's share price to reach $29.71 in the next year. This suggests a possible upside of 362.1% from the stock's current price. View analysts price targets for VSTM or view top …Dec 1, 2023 · Their VKTX share price targets range from $19.00 to $37.00. On average, they predict the company's stock price to reach $30.25 in the next twelve months. This suggests a possible upside of 132.5% from the stock's current price. View analysts price targets for VKTX or view top-rated stocks among Wall Street analysts. Dec 1, 2023 · CBAY Earnings Date and Information. CymaBay Therapeutics last posted its earnings results on November 7th, 2023. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.02.

All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange ...

Nov 14, 2023 · CymaBay Therapeutics Stock Forecast 2023. In the last five quarters, CymaBay Therapeutics’s Price Target has fallen from $29.28 to $23.09 - a -21.14% decrease. Five analysts predict that CymaBay Therapeutics’s share price will fall in the coming year, reaching $10.00. This would represent a decrease of -56.69%.

If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...In a recent transaction on November 17, 2023, Charles Mcwherter, the President of Research and Development at CymaBay Therapeutics Inc (NASDAQ:CBAY), sold 11,342 shares of the company's stock ... A high-level overview of CymaBay Therapeutics, Inc. (CBAY) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.(See CBAY stock forecast on TipRanks) AbSci Corporation . For the second penny stock we’ll look at, we’ll stick with the medical tech field – but look at a company with a different take on ...CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead ...Read Full Company Summary for ACIU here. View AC Immune ACIU investment & stock information. Get the latest AC Immune ACIU detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Newark, California-based CymaBay Therapeutics (CBAY) was approved for uplisting to the Nasdaq in June 2014, with stock initially trading at a value of $19. Across the next 9 years they have been ...Apr 26, 2023 · (See CBAY stock forecast)Cerevel Therapeutics (CERE)The next Edelman choice is Cerevel, a company established in 2018 that specializes in the field of neuroscience. Cerevel's focus is on the ... CymaBay Therapeutics ( NASDAQ: CBAY) is a clinical-stage biopharmaceutical company aiming to develop innovative treatments for liver diseases and other chronic conditions with high unmet medical ...

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce ...CymaBay Therapeutics Inc (CBAY) stock is trading at $11.76 as of 11:26 AM on Monday, Jul 3, a rise of $0.81, or 7.39% from the previous closing price of $10.95. The stock has traded between $10.95 and $11.77 so far today. Volume today is low. So far 1,522,720 shares have traded compared to average volume of 2,310,531 shares.TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comInstagram:https://instagram. 0gmfrc stcokalibaba usdividend stock calculator The current average CBAY price target, as estimated by these analysts, is $0.00. The predictions for the future CBAY stock price range from a low of $0.00 to a high of $0.00, highlighting the variability of market expectations for CBAY. View the latest CymaBay Therapeutics Inc. (CBAY) stock price, news, historical charts, analyst ratings and financial information from WSJ. us 30 year treasury yieldharley stocks Dec 1, 2023 · The consensus price target of analysts on Wall Street is $24.42, which implies an increase of 21.66% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20.00 and $34.00 respectively. As a result, CBAY is trading at a discount of -77.73% off the target high and -4.55% off the low. ure stock Sep 8, 2023 · Newark, California-based CymaBay Therapeutics (CBAY) was approved for uplisting to the Nasdaq in June 2014, with stock initially trading at a value of $19. Across the next 9 years they have been ... 3 Wall Street research analysts have issued 1-year price targets for Tecnoglass' shares. Their TGLS share price targets range from $43.00 to $54.00. On average, they anticipate the company's stock price to reach $48.20 in the next year. This suggests a possible upside of 30.2% from the stock's current price.EXEL Stock 12 Months Forecast. Based on 13 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $25.75 with a high forecast of $32.00 and a low forecast of $18.00. The average price target represents a 25.06% change from the last price of $20.59.